Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer  

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Yale Cancer Center Smilow Cancer Hospital 

Special Reports in Personalized Cancer Care

Videos

Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.


Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), Professor of Surgery (Oncology) and a member of the Cancer Prevention and Control Research Program at Yale Cancer Center was named a Fellow of the American Society of Clinical Oncology. 

Dr. Anees Chagpar Named 2021 ASCO Fellow

As one of the highest honors in the scientific field, Lieping Chen, MD, PhD, was elected to the National Academy of Sciences

Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians are presenting research studies at the 2021 Annual Virtual Meeting of the American Society of Clinical Oncology June 4-8. 

Yale Research to be Presented at 2021 ASCO Annual Meeting

Jan Philipp Bewersdorf, MD, discusses the role of allogeneic hematopoietic cell transplant in myelofibrosis.  



Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis 

Barbara Burtness, MD, has been appointed Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center. 

Barbara Burtness Named Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center

Joseph W. Kim, MD, Associate Professor of Medicine at Yale Cancer Center, has received a 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.

Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer. 

Yale Cancer Center Perspective Highlights New Advances for NSCLC

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.

Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.  



Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer 

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer. 










Dr. Lustberg Discusses Ongoing Research in Breast Cancer 

Margaret Gilshannon, MHA, has been appointed Deputy Director for Finance & Administration at Yale Cancer Center.

Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer Center

The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

Eric P. Winer, MD, will be appointed next director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale New Haven, effective February 1, 2022.

Eric P. Winer to lead Yale Cancer Center and Smilow Cancer Hospital

Terri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.  



Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma 

Findings from a new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity, which could help develop a new treatment strategy to benefit patients with melanoma and other cancers.

Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight Melanoma

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.  



Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer 

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer. 


Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer 

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers. 

Immunotherapy Advances Drive Progress in Lung Cancer Treatment 

Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.

Ian E. Krop, MD, PhD, Named Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research at Yale Cancer Center

New research led by Yale Cancer Center revealed White patients had significantly more telemedicine visits compared with Black patients for hematologic cancer care during the COVID-19 pandemic.

Yale Cancer Center Study Reveals Disparities in Telemedicine Use in Patients with Hematologic Cancers

The combination of ixabepilone and bevacizumab significantly improved progression-free survival vs ixabepilone alone in the treatment of platinum-resistant ovarian cancer, according to data from the phase 2 trial published in the British Journal of Cancer.

Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

Daniel P. Petrylak, MD, discusses the rationale for of the phase 1b/2 EV-103 trial in patients with muscle-invasive bladder cancer.


Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.

Yale Cancer Center and School of Public Health Receive Grant to Study Lifestyle Intervention in Women with Ovarian Cancer

Aarti Bhatia, MD, discusses the rationale for investigating berzosertib in this patient population, key updates from the phase 1 trial, and how these findings support the need for continued research of novel regimens in HNSCC.

Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC

Barbara Burtness, MD, has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center. 

Barbara Burtness Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital

An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection. 

Expert Insights on First-line Treatment Strategies in SCLC

Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.

Combination Therapy Approaches With Chemotherapy and  Immunotherapy in ES-SCLC

Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.

ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer. 

Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy  

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.

LAGOON and IMFORTE Trials: Data Updates and Expert Insights

Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.

2L Dosing Considerations and Management Strategies for SCLC 

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer. 

Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Latest Conference Coverage